Heard a crushing sound lately? It might have come the market's beat-down this week of three particularly unfortunate health-care stocks.
One of the week's biggest losers plunged on news of the U.S. Food and Drug Administration's denial of Breakthrough Therapy Designation for the company's lead drug. Another stock stumbled after investors learned that the company didn't disclose potential safety concerns from a clinical trial that ended early after meeting its primary endpoint. The third poor performer saw shares drop after announcing the departure of a top executive.
Which stocks got crushed the most this week? Find out by watching the following slideshow.
Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.